Unverified50% confidenceFactExact time
When AQP4 polarity is lost (such as in aging, ischemia or neurodegenerative disease), glymphatic flow rate drops significantly.
1
Sources
50%
Confidence
Long-term
Relevance
10/24/2026
First Seen
Sources
Related Entities
Related Claims
UnverifiedThe glymphatic clearance hypothesis faces controversy: imaging methods vary in reproducibility across laboratories; the causal relationship between AQP4 polarity loss and disease progression has not been fully established; and there is a lack of large-scale human trial evidence on whether enhancing glymphatic clearance can truly improve clinical outcomes.65% similarUnverifiedClinical trials show that lecanemab and donanemab can slow disease progression by approximately 25–35%, but they are only suitable for early-stage patients and carry risks of serious side effects such as brain hemorrhage and brain swelling60% similarUnverifiedThe longer the cold ischemia time, the greater the risk of organ function impairment and the more limited its usable range.56% similarUnverifiedIt is difficult to distinguish whether the biological age improvement brought about by GLP-1 drugs is a direct effect of the drugs or an indirect result of weight loss and metabolic improvement.53% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1094266API
curl https://kongchang.com/api/v1/knowledge/claims/1094266MCP
get_claim(id=1094266)